Recent data demonstrates that progression of prostate cancer involves interaction of PTEN and phosphoinosotide-3-kinase pathway and few biomarkers have been identified which may be therapeutic target of prostate cancer [28]. This evidence concerns the gene PTEN and Familial prostate cancer.